Hot Investor Mandate: Newly Established USA-Based VC Interested in Digital Health Technologies Including Digital Therapeutics, Smart Devices, Tech-Enabled Services

31 Mar

A newly established venture capital firm based in the US is expecting to close their first fund this year. The firm is seeking to invest in Seed to Series A companies. The firm expects to make about 80% of their investments in North America, but has a global outlook and has evaluated opportunities from Europe, Israel, and Asia.

Within life sciences, the firm is most interested in digital health technologies, including Digital Therapeutics, AI-powered healthcare solutions, smart devices, and tech enabled services. The firm will be extremely selective about medical device companies without a digital component. The same applies for traditional therapeutics and diagnostics sectors as well. The firm likes to see early traction (i.e. paying customer engagement), but is open to pre-revenue companies.

The firm is open to working with all kinds of management teams. The firm is capable of leading seed rounds and can act as either lead or co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: VC Fund Invests Broadly Across All Life Science Sectors With an Increased Interest in Medical Devices and Imaging Solutions, Can Help Companies Expand Into China Market

31 Mar

A US fund invests in early-stage startups in many industries with a preference for healthcare and IT technology. Typical equity investment size ranges from US$0.5-2 million in Pre-A to Series A stage companies. The firm is open to either leading or following in a syndicated round. The firm expects to make 10+ deals in the next 12 months and can invest globally with a focus on the US and Canada.

The firm considers broadly across healthcare industries including innovative drugs, medical devices, diagnostics, and digital health products. The firm has an increased interest in medical devices and imaging technology. The firm prefers companies that develop disruptive technologies to solve unmet medical needs.

The firm is looking for experienced management teams. The firm can leverage its innovation center in China to assist with commercialization in the China market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Seed Fund With US and China Offices Seeks to Invest in All Global Life Science Technologies With a Strong Focus on Diagnostics and Digital Health

31 Mar

An early-stage venture capital firm with offices in USA and China has 2 business practices; managing a seed fund that invests exclusively in healthcare and life sciences, and an advisory business primarily for western biotech or life science companies that are looking to establish business opportunities and partnerships in greater China. The firm is starting to expand their network into the Middle East, especially Turkey. The firm is looking for Seed opportunities but is open to participation in Pre-Seed and Series A on a case by case basis. The typical check size is $50-250K in the form of equity or convertible notes. The firm will consider opportunities anywhere in the world.

The firm will look at all subsectors and indications but is not investing in immunotherapy or cancer at this time. The firm is particularly interested in chronic disease, especially diabetes and is starting to look at neurodegenerative diseases as well.  The firm is not doing biotech deals, but they’ve done deals in Healthcare IT and the AI space. The firm is focusing on diagnostics and digital health at the moment.

The firm is open to all management teams but prefers teams with prior start-up experience. The firm is not looking to do small participations in big rounds and would prefer to do investments where their stake has a meaningful impact on the company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Digital RESI June Preliminary Agenda

24 Mar

By Rory McCann, Marketing Manager & Conference Producer, LSN

Digital RESI returns June 7-9 with virtual panel discussions designed to engage early-stage entrepreneurs and life science investors on strategies for success in fundraising. These conversations explore topics that are relevant to the early-stage ecosystem and provide insight to founders seeking capital and channel partners.

In addition to some topics back by popular demand, new topics will be introduced, such as partnerships with small and mid-sized pharma and the intersection of healthcare IT and medtech. Additionally, there will be two new topics in both the AI and longevity tracks, in addition to their popular Tales from the Road entrepreneur panels. 

Take advantage of these conversations and bring these perspectives into your own fundraising journey. Super early bird rates apply until April 15, so register early to save $300!

Digital RESI June 2022 Agenda

  Tuesday
(June 7)		 Wednesday
(June 8)		 Thursday
(June 9)
10AM EDT
Innovator’s Pitch Challenge Session #1
Innovator’s Pitch Challenge Session #5
Innovator’s Pitch Challenge Session #9
11AM EDT
Beyond Big Pharma Panel
Partnering & Perspectives from Small- and Mid-Sized Biotech
AI vs. Life Science Panel
Which Comes First in Early-Stage Investment? 
Age-Tech Care Management Panel
Technology Improving the Lives of Older Adults
12PM EDT
Entrepreneur Workshop
Entrepreneur Workshop
Entrepreneur Workshop
1PM EDT
Angels Investors Panel
Explaining the Process of Engagement
Corporate VC Panel
The Changing Landscape & New Opportunities
Impact Investors Panel
More Than Financial Returns
Innovator’s Pitch Challenge Session #2
Innovator’s Pitch Challenge Session #6
Innovator’s Pitch Challenge Session #10
2PM EDT
The Neuroscience of Aging Panel
Aging Impact on the Nervous System
Asia Cross-Border Panel
Building Global Partnerships
Team, Tech, & Traction in Early-Stage AI Panel
Building Your Startup as a Triple Threat
3PM EDT
Innovator’s Pitch Challenge Session #3
Innovator’s Pitch Challenge Session #7
Software-Enabled Medical Devices
Investing at the Intersection of Digital Health and Medtech
4PM EDT
Tales from the Road: AI Innovation in Healthcare
Standing Out in a Growing Field
Tales from the Road: Age-Related Diseases
Developing Prevention & Treatments
Tales from the Road: Biotech and MedTech Innovators
Entrepreneurs on Their Fundraising Journey
5PM EDT
Innovator’s Pitch Challenge Session #4
Innovator’s Pitch Challenge Session #8
Innovator’s Pitch Challenge Session #11

Digital RESI March at-a-Glance

24 Mar

By Karen Deyo, Director of Investor Research, Israel BD, LSN

Digital RESI March is in its final stretch, with many successful panels, workshops, and pitch sessions complementing three days full of partnering meetings. For companies and investors attending RESI, it has become a forum to build and maintain relationships, using RESI’s unique partnering platform to learn detailed information about each other that is frequently not readily available online. Whether meeting within RESI, or scheduling meetings in the weeks following, RESI provides its constituents with an opportunity to use a targeted approach to finding partners who are a fit for them.

Even with a return to in-person events, RESI attendees have shown that virtual events, or even a virtual component to events, have become a critical component of early-stage partnering. Virtual events have allowed companies and investors to expand their partnering activities, even if their schedule is too busy to allow travel. Furthermore, companies can now stretch their fundraising budgets further. There is no replacement for in-person events, and the ability to attend networking events and the connections formed there will remain an important part of any company’s fundraising journey, but virtual partnering will remain an important part in expanding a company’s reach.

The Digital RESI model would not have seen the success it has over the past couple of years without the enthusiastic support of our community. Thank you to the startups, investors, and service providers who return to RESI and add value to the early-stage ecosystem Check out our attendee breakdown from March:

If you missed Digital RESI March, do not worry! Digital RESI returns June 7-9 – Sign up today for super early bird rates and save $300!

Fundraising Bootcamps for Life Science Start-ups

24 Mar

By Candice He, Vice President of Business Development, Global Investment Strategist, LSN

For the past decade, Life Science Nation (LSN) has worked with thousands of life science start-ups on building connections with investors and strategic partnerships through the Redefining Early Stage Investments (RESI) conference series and the LSN Investor Database. LSN has developed rich insights and strategies to help early-stage founders on their fundraising campaigns and efficient partnering. It is our goal to help the community thrive by delivering a series of free fundraising bootcamps as companions to the RESI series. These bootcamps cover many of these topics:

  • Identifying your investors and building your global target list (GTL)
  • Preparing for the Innovator’s Pitch Challenge (IPC)
  • Keys to Successful Partnering
  • Branding & Messaging: From Seed to Series B

Access recordings of former fundraising bootcamps!

Digital RESI March recently featured a popular bootcamp, Branding & Messaging: From Seed to Series B. This session informs scientist-entrepreneurs on how to tell their company story through a cogent set of marketing materials to successfully bridge the gap from academia to start-up and move into the business development domain.

Stay tuned for the schedule of newest fundraising bootcamps this spring! If you’re interested in LSN’s lineup of entrepreneur education programs, please feel free to contact our business development team.

Want to learn more? The Business Development team at Life Science Nation is available to answer questions and share additional details to help you meet your partnership goals!
International
East Coast (USA) & China
Midwest (USA)
& Canada
West Coast  (USA)
Alex
Greg Mannix
Vice President International Business Development
Book a Meeting
Email Me
Candice He
VP, Business Development & Global Investment Strategist
Book a Meeting
Email Me
Antoinette Lowre
Manager of Business Development
Book a Meeting
Email Me
Alexander Vassallo
Manager of Business Development
Book a Meeting
Email Me

Hot Investor Mandate: Venture Arm of Family Office Invests Globally and Broadly Across All Life Science Sectors From Seed to Series C

24 Mar

A venture arm of a family office invests in all sectors of the life sciences, looking for companies that are 2-5 years from exit. The firm invests globally, although they have a preference for companies based in the UK and in Central/Eastern Europe. The firm invests from Seed-Series C, and generally will invest $1-5M per round.

The firm is both sector and indication agnostic, and is less focused on stage of development and more focused on time to exit, looking for companies with a strategy that will allow them to exit within 2-5 years after the investment.

The firm generally does not act as a lead investor. The firm does not generally take a board seat, and is usually a silent investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →